➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Express Scripts
Johnson and Johnson
McKesson
Colorcon

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GLEEVEC

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Gleevec

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00022737 ↗ Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 2002-10-01 This phase II trial is studying how well combination chemotherapy with or without donor peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia. Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
NCT00025246 ↗ Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery Completed National Cancer Institute (NCI) Phase 2 2001-09-01 This phase II trial is studying how well imatinib mesylate works in treating patients with gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
NCT00027586 ↗ Imatinib Mesylate in Treating Patients With Metastatic Melanoma Completed National Cancer Institute (NCI) Phase 2 2001-09-01 RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
NCT00027586 ↗ Imatinib Mesylate in Treating Patients With Metastatic Melanoma Completed M.D. Anderson Cancer Center Phase 2 2001-09-01 RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
NCT00028002 ↗ Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor Completed American College of Radiology Imaging Network Phase 2 2002-02-01 Phase II trial to study the effectiveness of neoadjuvant and adjuvant imatinib mesylate in treating patients who are undergoing surgery for primary or recurrent malignant gastrointestinal stromal tumor. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving imatinib mesylate before and after surgery may shrink the tumor so it can be removed and may kill any tumor cells remaining after surgery.
NCT00028002 ↗ Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor Completed Eastern Cooperative Oncology Group Phase 2 2002-02-01 Phase II trial to study the effectiveness of neoadjuvant and adjuvant imatinib mesylate in treating patients who are undergoing surgery for primary or recurrent malignant gastrointestinal stromal tumor. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving imatinib mesylate before and after surgery may shrink the tumor so it can be removed and may kill any tumor cells remaining after surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gleevec

Condition Name

Condition Name for Gleevec
Intervention Trials
Leukemia 27
Chronic Myeloid Leukemia 13
Chronic Myelogenous Leukemia 13
Gastrointestinal Stromal Tumor 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gleevec
Intervention Trials
Leukemia 85
Leukemia, Myeloid 70
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 68
Leukemia, Myeloid, Chronic-Phase 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gleevec

Trials by Country

Trials by Country for Gleevec
Location Trials
United States 439
Canada 37
China 32
Australia 26
United Kingdom 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gleevec
Location Trials
Texas 51
California 29
Pennsylvania 28
New York 27
Illinois 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gleevec

Clinical Trial Phase

Clinical Trial Phase for Gleevec
Clinical Trial Phase Trials
Phase 4 3
Phase 3 15
Phase 2/Phase 3 2
[disabled in preview] 163
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gleevec
Clinical Trial Phase Trials
Completed 117
Terminated 23
Active, not recruiting 15
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gleevec

Sponsor Name

Sponsor Name for Gleevec
Sponsor Trials
National Cancer Institute (NCI) 49
Novartis 32
M.D. Anderson Cancer Center 29
[disabled in preview] 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gleevec
Sponsor Trials
Other 174
Industry 106
NIH 53
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Merck
Baxter
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.